Lancet reports yearly screening for ovarian cancer, using a pelvic ultrasound and checking a blood marker CA125, might reduce deaths from ovarian cancers. The study was done in UK in over 200,000 post menopausal women with no family or personal history of ovarian cancer and they were followed for a period of 11 years.
During the follow-up, the incidence of ovarian cancer mortality was not significantly lower in the screening group than in the no-screening group. However, the effect of screening became significant after 7 years. In addition, in a prespecified secondary analysis that excluded women with CA125 levels suggesting cancer at baseline, screening was associated with a 20% reduction in ovarian cancer mortality relative to no screening.